



FOR RELEASE, April 8th, 2008

Trinity to Place \$7.1 Million of American Depository Shares

DUBLIN, Ireland April 8th 2008...- Trinity Biotech plc (Nasdaq: [TRIB](#)), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it has obtained commitments from a select group of institutional investors in the USA to purchase approximately 1.8 million American Depository Shares at a price of \$3.92 per ADS in a registered public offering. This represents a discount of 15% to the closing price on NASDAQ on April 7, 2008. Investors also will receive 5 year warrants to purchase an aggregate of approximately 545,000 American Depository Shares at an exercise price of \$5.54 per share, representing a 41% premium to the placement price. These warrants are callable by the Company if the share price exceeds \$11.08 for 20 consecutive trading days.

The closing is expected to take place on Friday, April 11, 2008, subject to the satisfaction of customary closing conditions.

Trinity Biotech intends to use these funds for general corporate purposes and the repayment of the final deferred consideration from the 2006 bioMerieux acquisition.

The American Depository Shares and warrants are being sold under a previously filed shelf registration statement, which the Securities and Exchange Commission has declared effective. This press release shall not constitute an offer to sell nor the solicitation of an offer to buy, nor shall there be any sales of these securities in any jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and blood coagulation disorders, and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: www.trinitybiotech.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialization and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Contact : Trinity Biotech plc
Kevin Tansley - CFO
(353)-1-2769800
E-mail: kevin.tansley@trinitybiotech.com

END OF RELEASE